Uracil derivatives as TRPA1 inhibitors

US11858921B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Florian Paul Christian Binder · Maselheim, DE
• Martin Fleck · Warthausen, DE
• Jens WILLWACHER · Biberach an der Riß, DE

Key dates

• Filing date: Apr 13, 2022
• Grant date: Jan 2, 2024
• Expiry date: Apr 13, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present disclosure provides certain uracil derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.